Zai Lab (HKSE:09688) Total Current Assets : HK$8,098 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Zai Lab's total current assets for the quarter that ended in Mar. 2025 was HK$8,098 Mil.

Zai Lab Total Current Assets Historical Data

The historical data trend for Zai Lab's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Total Current Assets Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

9,426.59

11,705.37

8,753.41

7,338.14

8,165.80

Zai Lab Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															6,951.83	6,794.10	6,704.54	8,165.80	8,098.23

Zai Lab Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Zai Lab's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6060.663	+	695.027	+	309.964	+	1100.147
	=	8,166

Zai Lab's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5886.054	+	681.465	+	412.378	+	1118.335
	=	8,098

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Zai Lab (HKSE:09688) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Zai Lab's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5886.054	-	2818.239	+	0.75 * 595.047	+	0.5 * 412.378
=	3,720

Zai Lab Total Current Assets Related Terms

Thank you for viewing the detailed overview of Zai Lab's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ZLAB:USA ZLAB N:Mexico 1ZLB:Germany 1ZLB:Germany 1ZL:Germany 1ZL:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Executives

Fmr Llc	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Du Ying	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Janus Henderson Group Plc	2102 Investment manager
Ubs Group Ag	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc.	2102 Investment manager
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Baillie Gifford & Co	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent

Zai Lab Headlines

No Headlines